NEW YORK (GenomeWeb) – Fluidigm reported after the close of the market on Thursday that its fourth quarter revenues jumped 17 percent year over year driven in large part by its mass cytometry business.

For the three months ended Dec. 31, the South San Francisco, California-based life science research tools firm tallied revenues of $32.3 million compared to $27.7 million a year ago and besting analysts' average estimate of $30.6 million. The company also bested previous guidance of Q4 revenues of $29 million to $32 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.